目的 探討注射用益氣復(fù)脈（凍干）聯(lián)合阿托伐他汀治療冠心病并心力衰竭的臨床效果。方法 選取2021年4月—2023年4月貴州省第二人民醫(yī)院收治的100例冠心病合并心力衰竭患者為研究對象，根據(jù)治療方案不同分為對照組和試驗組，每組各50例。對照組在常規(guī)治療基礎(chǔ)上口服阿托伐他汀鈣片，每次20 mg，每日1次；試驗組在對照組基礎(chǔ)上加用注射用益氣復(fù)脈（凍干），每次5.2 g加入250～500 mL 5%葡萄糖注射液或0.9%氯化鈉注射液稀釋后靜脈滴注，每日1次，兩組均連續(xù)用藥14 d。觀察兩組患者的療效，比較治療前后兩組患者心功能指標(biāo)［腦鈉肽（BNP）、左室射血分?jǐn)?shù)（LVEF）］、血脂指標(biāo)［總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白-膽固醇（LDL-C）、高密度脂蛋白-膽固醇（HDL-C）］變化，觀察治療期間不良反應(yīng)發(fā)生情況。結(jié)果 試驗組治療總有效率96.0%，顯著高于對照組82.0%（P＜0.05）。治療前，兩組患者心功能指標(biāo)及血脂指標(biāo)比較，差異均無統(tǒng)計學(xué)意義（P＞0.05）。治療后，兩組患者血清BNP、TC和LDL-C水平均較本組治療前顯著降低（P＜0.05），LVEF水平均較本組治療前顯著升高（P＜0.05），且試驗組與對照組比較，上述各項指標(biāo)改善效果更顯著（P＜0.05）。治療期間，兩組患者均各有3例患者出現(xiàn)輕度惡心，不良反應(yīng)總發(fā)生率比較，差異無統(tǒng)計學(xué)意義（P＞0.05）。結(jié)論 注射用益氣復(fù)脈（凍干）聯(lián)合阿托伐他汀鈣片治療冠心病合并心力衰竭療效顯著，可改善患者心功能及血脂，安全性較高。

Objective To investigate the clinical effect of Yiqi Fumai Lyophilized Injection combined with atorvastatin in the treatment of coronary heart disease with heart failure. Method A total of 100 patients with coronary heart disease and heart failure admitted to the Second People's Hospital of Guizhou Province from April 2021 to April 2023 were selected as the research subjects. They were divided into a control group and an experimental group based on different treatment plans, with 50 patients in each group. Patients in the control group took orally Atorvastatin Calcium Tablets, 20 mg each time, once a day on the basis of conventional treatment. Patients in the experimental group was supplemented with injection of Yiqi Fumai Lyophilized Injection on the basis of the control group. Each time, 5.2 g was added, and 250-500 mL of 5% Glucose Injection or 0.9% Sodium Chloride Injection was diluted before intravenous drip, once a day. Both groups were treated continuously for 14 days. The curative effect of the two groups of patients was observed. The cardiac function indicators [brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF)], blood lipid indicators [total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)] of the two groups of patients were compared before and after treatment. The occurrence of adverse reactions was observed during treatment. Results The total effective rate of the experimental group was 96.0%, significantly higher than the control group's 82.0% (P＜0.05). Before treatment, there was no statistically significant difference (P＞0.05) in the comparison of cardiac function indicators and blood lipid indicators between the two groups of patients (P＞0.05). After treatment, the serum levels of BNP, TC, and LDL-C in both groups of patients were significantly reduced compared to before treatment in same group (P＜0.05), and the LVEF levels were significantly increased compared to before treatment in same group (P＜0.05). Moreover, compared with the control group, the improvement effect of the above indicators in the experimental group was more significant (P＜0.05). During the treatment period, both groups of patients had three cases of mild nausea, and there was no statistically significant difference in the total incidence of adverse reactions (P＞0.05). Conclusion Yiqi Fumai Lyophilized Injection combined with Atorvastatin Calcium Tablet is effective in the treatment of coronary heart disease with heart failure, and can improve the heart function and blood lipids of patients with high safety.

R972